title: N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies.
abstract: Therapeutic proteins contain a large number of post-translational modifications, some of which could potentially impact their safety or efficacy. In one of these changes, pyroglutamate can form on the N terminus of the polypeptide chain. Both glutamine and glutamate at the N termini of recombinant monoclonal antibodies can cyclize spontaneously to pyroglutamate (pE) in vitro. Glutamate conversion to pyroglutamate occurs more slowly than from glutamine but has been observed under near physiological conditions. Here we investigated to what extent human IgG2 N-terminal glutamate converts to pE in vivo. Pyroglutamate levels increased over time after injection into humans, with the rate of formation differing between polypeptide chains. These changes were replicated for the same antibodies in vitro under physiological pH and temperature conditions, indicating that the changes observed in vivo were due to chemical conversion not differential clearance. Differences in the conversion rates between the light chain and heavy chain on an antibody were eliminated by denaturing the protein, revealing that structural elements affect pE formation rates. By enzymatically releasing pE from endogenous antibodies isolated from human serum, we could estimate the naturally occurring levels of this post-translational modification. Together, these techniques and results can be used to predict the exposure of pE for therapeutic antibodies and to guide criticality assessments for this attribute.
authors.affiliation: Department of Process and Product Development, Amgen Inc., Thousand Oaks, California 91320, USA.
authors.forename: Y Diana
authors.initials: YD
authors.lastname: Liu
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Goetze
authors.forename: Randal B
authors.initials: RB
authors.lastname: Bass
authors.forename: Gregory C
authors.initials: GC
authors.lastname: Flynn
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D019843:Archaeal Proteins / Q000737:chemistry; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D018698:Glutamic Acid / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational; D020027:Pyrococcus furiosus / Q000201:enzymology; D011751:Pyroglutamyl-Peptidase I / Q000737:chemistry; D011761:Pyrrolidonecarboxylic Acid / Q000737:chemistry* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D019843:Archaeal Proteins; D007074:Immunoglobulin G; D018698:Glutamic Acid; D011751:Pyroglutamyl-Peptidase I; D011761:Pyrrolidonecarboxylic Acid